- Home
- FGB vs IFRX Comparison
FGB vs IFRX Comparison
Compare FGB & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- IFRX
- Stock Information
- Founded
- FGB 2007
- IFRX 2007
- Country
- FGB United States
- IFRX Germany
- Employees
- FGB N/A
- IFRX N/A
- Industry
- FGB Finance/Investors Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- FGB Finance
- IFRX Health Care
- Exchange
- FGB Nasdaq
- IFRX Nasdaq
- Market Cap
- FGB 58.9M
- IFRX 65.8M
- IPO Year
- FGB N/A
- IFRX 2017
- Fundamental
- Price
- FGB $4.01
- IFRX $0.84
- Analyst Decision
- FGB
- IFRX Strong Buy
- Analyst Count
- FGB 0
- IFRX 4
- Target Price
- FGB N/A
- IFRX $7.75
- AVG Volume (30 Days)
- FGB 53.0K
- IFRX 753.4K
- Earning Date
- FGB 01-01-0001
- IFRX 05-07-2025
- Dividend Yield
- FGB 8.92%
- IFRX N/A
- EPS Growth
- FGB N/A
- IFRX N/A
- EPS
- FGB N/A
- IFRX N/A
- Revenue
- FGB N/A
- IFRX $140,242.00
- Revenue This Year
- FGB N/A
- IFRX $3.36
- Revenue Next Year
- FGB N/A
- IFRX $100.60
- P/E Ratio
- FGB N/A
- IFRX N/A
- Revenue Growth
- FGB N/A
- IFRX 30.90
- 52 Week Low
- FGB $2.85
- IFRX $0.71
- 52 Week High
- FGB $3.74
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- FGB 51.99
- IFRX 32.37
- Support Level
- FGB $3.97
- IFRX $0.78
- Resistance Level
- FGB $4.11
- IFRX $0.89
- Average True Range (ATR)
- FGB 0.09
- IFRX 0.12
- MACD
- FGB 0.00
- IFRX -0.13
- Stochastic Oscillator
- FGB 25.00
- IFRX 7.78
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.